The litigation centers on the clinical development of Fianlimab in combination with Libtayo, a treatment Regeneron had repeatedly touted as a potential blockbuster. The lawsuit, spearheaded by the firm Hagens Berman, alleges that company management misled shareholders by maintaining an optimistic outlook while failing to disclose that the trial’s statistical assumptions were fundamentally flawed and that the treatment was not showing meaningful differentiation over existing therapies.
In section Releases
Regeneron Faces Securities Lawsuit After Failed Melanoma Trial
A $11 billion collapse in market capitalization has triggered a class action lawsuit against Regeneron Pharmaceuticals, following the company's disclosure that a late-stage clinical trial for its melanoma therapy failed to meet primary efficacy goals, leaving investors who purchased stock between August 2025 and May 2026 facing significant losses.
Investors contend that Regeneron masked the trial's shortcomings by attributing slow event rates—such as disease progression or death—to the success of the treatment arms. The discrepancy between management's public confidence and the internal reality began to surface in April 2026, when the company abruptly altered its trial protocol. By May 15, 2026, Regeneron confirmed the study had failed to achieve statistical significance for progression-free survival, leading to a sharp decline in share price. Hagens Berman partner Reed Kathrein stated the investigation aims to determine if the firm intentionally delayed protocol disclosures to hide the lack of clinical efficacy. Affected investors have until September 14, 2026, to file as lead plaintiffs in the pending case.
Comments (0)
No comments yet. Be the first!